Tandem Diabetes (TNDM) Misses Q1 EPS by 16c

Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.23), $0.16 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $175.9 million versus the consensus estimate of $168.43 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $850-865 million, versus the consensus of $846.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Dollar General (DG) Tops Q2 EPS by 48c, Beats on Revenue; Offers FY27 EPS Guidance
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance